What do systematic reviews say?

14 questions · 14 findings · 1 reviews · HIV/AIDS

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 14 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- PRO 140 vs placebo · Antiviral response: 2 mg/kg
  Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 27.44 [1.25, 601.57]
  1 study · 19 participants
  Very low
Direct match · question page
- PRO 140 vs placebo · Antiviral response: 10 mg/kg
  Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 145.67 [5.3, 4004.91]
  1 study · 21 participants
  Very low
Direct match · question page
- PRO 140 vs placebo · Antiviral response: 5 mg/kg
  Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 439.09 [25.73, 7493.14]
  2 studies · 40 participants
  Very low
Direct match · question page
- PRO 140 vs placebo · Individual nadir changes in HIV‐1 RNA level: 2 mg/kg
  Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low
Direct match · question page
- PRO 140 vs placebo · Antiviral response: 0.5 mg/kg
  Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 3 [0.11, 83.36]
  1 study · 19 participants
  Very low

PRO 140 vs placebo

Antiviral response ‐ 0.5mg/Kg · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 0.5 mg/kg compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 3 [0.11, 83.36]
1 study · 19 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level ‐ 5mg/Kg · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level: 10 mg/kg · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level ‐ 162 mg weekly · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level ‐ 324 mg weekly · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level ‐ 324 mg biweekly · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

PRO 140 vs placebo

Antiviral response ‐ 2mg/Kg · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 2 mg/kg compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 27.44 [1.25, 601.57]
1 study · 19 participants
Very low

PRO 140 vs placebo

Antiviral response ‐ 5mg/Kg · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 439.09 [25.73, 7493.14]
2 studies · 40 participants
Very low

PRO 140 vs placebo

Antiviral response: 10 mg/kg · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 10 mg/kg compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 145.67 [5.3, 4004.91]
1 study · 21 participants
Very low

PRO 140 vs placebo

Antiviral response ‐ 162 mg weekly · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 162 mg weekly compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 24.82 [1.17, 527.12]
1 study · 21 participants
Very low

PRO 140 vs placebo

Antiviral response ‐ 324 mg weekly · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 324 mg weekly compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 147 [5.35, 4037.48]
1 study · 21 participants
Very low

PRO 140 vs placebo

Antiviral response ‐ 324 mg biweekly · patients being treated for HIV infection

It is very uncertain whether PRO 140 changes antiviral response: 324 mg biweekly compared with placebo (very low certainty).

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
OR 57 [2.59, 1253.22]
1 study · 22 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level ‐ 0.5mg/Kg · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

PRO 140 vs placebo

Individual nadir changes in HIV‐1 RNA level ‐ 2mg/Kg · patients being treated for HIV infection

1 finding from 1 review

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low